CNSI Selects Edifecs Healthcare Accelerator Suite(TM) for MMIS Solution to Support South Dakota Medica... (ows first-hand the importance ofstandard...)

CNSI Selects Edifecs Healthcare Accelerator Suite(TM) for MMIS Solution to Support South Dakota Medicaid Program

Date:11/26/2008

ows first-hand the importance of standardizing electronic transactions and identifying patterns in the Healthcare Value Chain. It's an area that he's been intimately involved with since Edifecs' inception.

"We are delighted that CNSI has selected Edifecs as a partner and are pleased to play a key role in updating the State's MMIS Drug Claims processing solution, said Sunny. Edifecs Healthcare Accelerator is the most widely deployed HIPAA validation solution on the market, and we are very happy to welcome CNSI to Edifecs' family of partners. CNSI can now benefit from the integration of Edifecs Healthcare Accelerator with their eCams 2.0 product to fully validate transactions across all healthcare standards, including HIPAA, HL7, NCPDP, emerging XML standards, and many more."

About CNSI

CNSI is a full-service IT business solutions provider that has enjoyed steady growth since its incorporation in 1994. Headquartered in Rockville, Maryland with offices throughout the U.S., CNSI delivers a broad portfolio of IT and business process outsourcing solutions to a diverse base of commercial and government clients, including Department of Homeland Security, Federal Aviation Administration, Department of Energy, Amtrak, and several state agencies. For more information, please visit http://www.cns-inc.com.

About Edifecs, Inc.

Edifecs helps organizations achieve interoperability and return on investment by simplifying the adoption of standard electronic transactions and deriving business value from trading partner communities. 2008 marks 12 years of Edifecs' expertise in providing innovative technology solutions to over 1000 clients worldwide. Founded in 1996, Edifecs is headquartered in Bellevue, WA. Company website: http://www.edifecs.com. Contact: Kevin Pierce

SOURCE Edifecs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Citizens Republic Bancorp Selects HealthPlus as Sole Provider of Health Insurance for 2009
2. uTraxx Selects Birdstep Technology's RDM Server for its Next Generation Business Process Management Software
3. Kindred Healthcare, Nations Largest Post-Acute Healthcare Provider, Selects Allscripts Referral Management
4. Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare
5. College of American Pathologists Selects Charles Roussel as Its New Executive Vice President
6. HealthMetrix Research Selects 2009 Medicare Advantage Plans for Best Overall Benefit Value
7. Patient Placement Systems Selects Iatric Systems, Inc. to Deliver Interfaces for MEDITECH Healthcare Information Systems
8. Medical Reimbursement Consultants, Inc. Selects LeonardoMD for Web-based Medical Billing
9. 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program
10. Swiss Medical Group Selects ILog JRules to Streamline Claims Processing
11. Unisys Selects Edifecs Healthcare Accelerator Suite(TM) for MMIS System

Post Your Comments:

(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also

(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be

(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa

(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa

(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju

Breaking Medicine News(10 mins):Health News:Free Health Clinic Event Is Not Just for the Sick 2 Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2 Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3 Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2 Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3 Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4 Health News:Human guinea pigs wary of high-paying medical trials 2 Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2

[0] Free Health Clinic Event Is Not Just for the Sick [0] The Leapfrog Group Releases Its 2009 Top Hospitals List [0] Muscle cell infusion shown to strengthen sphincters in animals in Stanford study [0] Human guinea pigs wary of high-paying medical trials [0] Timing of Multiple-Ligament Knee Surgery May Not Matter

... WEDDLE,s, the largest publisher of print gu...009 User,s Choice Awards. Absolutely Health Care, ...d medical jobs is pleased to receive this prestigi...ere actual users such as job seekers, employers, a...

... Company leads industry in providing medical...e Base tool. , Lake Fores...e Technologies announces a comprehensive initiativ...rt of Scribe,s continuing strategy to provide tran...

... SpectraScience, Inc. (OTC Bulletin Board: SCIE), ...d today that it has entered into a $6.0 million co...Fund II, LLC, a Chicago-based institutional invest... the Securities and Exchange Commission has declar...

...., Feb. 4 drugstore.com , inc.,(Nasdaq: DSCM )...ion, and,pharmacy products, today announced its fi...year ended December 28, 2008. The company reporte...d EBITDA,in the history of the company of $5.2 mil...

...4 The Elton John AIDS Foundation announced today ...erform at the 17th Annual Elton John AIDS Foundati...y, February 22, 2009, at the Pacific Design Center...h1. , , Oakland native Raphael Saadiq made his en...

...red Hispanic children will receive coverage , , W...ignificant downpayment on his commitment to make h... L. Delgado, President and CEO of the National All...ize the State Children,s Health Insurance Program ...

For the Third Year in a Row, Absolutely Health Care is Awarded a WEDDLE's User's Choice Award Scribe Healthcare Technologies, LLC to Integrate BenchMark KB™ in Scribe Complete™ Medical Documentation Platform SpectraScience, Inc. Enters Into $6.0 Million Common Stock Purchase Agreement drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales Three-Time Grammy Nominee Raphael Saadiq to Perform at 17th Annual Elton John AIDS Foundation Academy Awards(R) Viewing Party SCHIP Brings Relief to Modest-Income Families

(Date:12/3/2009)MADISON, N.J., Dec. 3 A genetic variation that may indicate a patient,s risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is

(Date:12/3/2009)SAN DIEGO, Dec. 3 BioMed Realty Trust, Inc. (NYSE: BMR ) announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square

(Date:12/3/2009)HOERSHOLM, Denmark and SAN DIEGO, California, December 3 , - SPC3649 Successfully Inhibits miR-122, a microRNA Important for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatiti

Breaking Medicine Technology:Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2 Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3 BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2 BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3 New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2 New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3 New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4 New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5 Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 1 Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 2 Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 3 Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 4 Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 5 Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 6 Caraco Pharmaceutical Laboratories Ltd Reports Results for the First Quarter of Fiscal Year 2010 52994 7 Stent Studies Tied to Rapid Changes in Use 52992 1 Stent Studies Tied to Rapid Changes in Use 52992 2 DURECT to Present at the BMO Capital Markets Healthcare Conference 52990 1 DURECT to Present at the BMO Capital Markets Healthcare Conference 52990 2

[0] Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition [0] BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark [0] New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C

...27 A doctor who is,internationally recognized for...cally for research on DHA, an omega-3 fatty acid, ...d for outstanding achievement in the field,of mate...as among the first to report that infants,receivin...oic acid) levels,than formula-fed infants and the ...

...ur Years of Treatment Presented at ICAAC/IDSA,2008...ough,Corporation (NYSE: SGP ) today reported a da...tional CCR5 receptor antagonist, demonstrated,sust...nts and was well,tolerated through up to four year... patients. Vicriviroc was administered once-daily ...

Other Medicine Technology:March of Dimes Honors Dr. Susan Carlson for Outstanding Work In Maternal-Fetal Nutrition 2 Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 2 Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 3 Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 4 Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 5 Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 6

March of Dimes Honors Dr. Susan Carlson for Outstanding Work In Maternal-Fetal Nutrition Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients

DNA Engine Thermal Cycler Chassis, w/96-well block & motorized lid

DNA Engine Thermal Cycler Chassis

MBS Satellite Thermal Cycler 0.5ml

MBS Satellite Thermal Cycler 0.2ml

Medicine Products:

DNA Engine Thermal Cycler Chassis, w/96-well block & motorized lid DNA Engine Thermal Cycler Chassis MBS Satellite Thermal Cycler 0.5ml MBS Satellite Thermal Cycler 0.2ml

CNSI Selects Edifecs Healthcare Accelerator Suite(TM) for MMIS Solution to Support South Dakota Medica...(ows first-hand the importance ofstandard...),Health